Synopsis: Patients treated with vascular interventions for peripheral artery disease (PAD) have a higher risk of lower limb complications and cardiovascular events. Even after revascularization, several symptoms such as severe cloudification, limb ischemia, myocardial infarction, and other cardiovascular complications can exist. This “ Med Fact ” discusses a clinical trial, “ The safety and efficacy of Rivaroxaban in reducing the risk of major thrombotic and cardiovascular events in patients with PAD ”, from The New England Journal Of Medicine . Authors: Marc P. Bonaca, Rupert M.
Bauersachs, et al. What was the need for this study? Oral anticoagulants inhibit the thrombin-mediated activation of platelets and prevent the incidence of acute limb ischemia and cardiovascular events. Several trials have shown that the addition of anticoagulants to conventional aspirin therapy can reduce the…
